ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete- response rate and durable disease control.
John F. Seymour(The Royal Melbourne Hospital), Andrew W. Roberts(The Royal Melbourne Hospital), Martin Dunbar(AbbVie (United States)), Lori A. Gressick(AbbVie (United States)), Sari H. Enschede(AbbVie (United States)), Nikita Rudersdorf(AbbVie (United States)), Thomas J. Kipps(University of California San Diego), Nicholas P. Montalvo(AbbVie (United States)), David C.S. Huang(The University of Melbourne), John M. Pagel(University of Washington), Rod Humerickhouse(Abbott Fund), Matthew S. Davids(Harvard University), Brad S. Kahl(UW Health University Hospital), John F. Gerecitano(Memorial Sloan Kettering Cancer Center), Ming Zhu(AbbVie (United States)), William G. Wierda(University of Maryland, Baltimore), Mary Ann Anderson(The Royal Melbourne Hospital), Elisa Cerri(AbbVie (United States)), Jianning Yang(AbbVie (United States)), Soham D. Puvvada(University of Arizona)
Cited by 56
Related Papers
ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets
|Nature Medicine|2013|3k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k